{
  "doc_id": "aspen_parenteral_nutrition_pn_and_home_pn__57ff81",
  "original_filename": "ASPEN Parenteral Nutrition (PN) and Home PN.pdf",
  "md_path": "data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/ASPEN Parenteral Nutrition (PN) and Home PN.md",
  "rmd_path": "data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/ASPEN Parenteral Nutrition (PN) and Home PN.rmd",
  "blocks": [
    {
      "type": "image",
      "section": "",
      "line": 0,
      "content": "![img-0.jpeg](images/87821306c5ba38e8.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course",
      "line": 2
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 4
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 6,
      "preview": "**Wednesday, August 6, 2025**"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 8,
      "preview": "**3:00 pm \u2013 4:30 pm ET**"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SESSION HANDOUT",
      "line": 10
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 12,
      "preview": "|   | Page  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 13,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 14,
      "preview": "|  Accreditation Information | 2  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 15,
      "preview": "|  How to Claim CE Credit and Access CE Transcript | 3-6  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 16,
      "preview": "|  How to Access Recording and Handout | 7  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 17,
      "preview": "|  Session Slides | 8-54  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 18,
      "preview": "|  Self-Assessment Q&A | 55-57  |"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 20,
      "preview": "--- page 1 ---"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 22,
      "preview": "Nutrition Support Fundamentals Course: Parenteral Nutrition (PN) and Home PN August 6, 2025, 3:00 pm"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 24,
      "preview": "Course Goal and Target Audience: The American Society for Enteral and Parenteral Nutrition (ASPEN) p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Course Objectives:",
      "line": 26
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 28
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 30,
      "preview": "1. Identify current indications for parenteral nutrition"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 31,
      "preview": "2. Discuss parenteral formula and admixture design"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 32,
      "preview": "3. Evaluate components of parenteral nutrition monitoring and management"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 33,
      "preview": "4. Identify key safe practice issues related to parenteral nutrition"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 35,
      "preview": "Successful Completion: CE credit must be claimed by September 6, 2025. To obtain credit for the webi"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 37,
      "preview": "Pharmacists and physicians, please note that ASPEN will upload earned CE credit into the appropriate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Policies and Information:",
      "line": 39
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 41,
      "preview": "Non-Commercialism. ASPEN subscribes to the Standards for Integrity and Independence in Accredited Co"
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 43,
      "preview": "Privacy and Confidentiality. ASPEN respects the privacy of its members and customers. Companies that"
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 45,
      "preview": "Grievances. Grievances must be submitted in writing to Senior Director, Education and Research at AS"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Commercial Support and Sponsorship:",
      "line": 47
    },
    {
      "type": "text",
      "section": "Commercial Support and Sponsorship:",
      "line": 49,
      "preview": "Commercial Support: None"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Accreditation Statement",
      "line": 51
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 53,
      "preview": "In support of improving patient care, The American Society for Parenteral and Enteral Nutrition (ASP"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 55,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 57,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 59,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 61,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 63,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 64,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 65,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 66,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 67,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 68,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 69,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 70,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 72,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 74,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 76,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 78,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 80,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 81,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 82,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 83,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 84,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 85,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 86,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 87,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 89,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 91,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 93,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 95,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 97,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 98,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 99,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 100,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 101,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 102,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 103,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 104,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 106,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 108,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 110,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 112,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 114,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 115,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 116,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 117,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 118,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 119,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 120,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 121,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 123,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 125,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 127,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 129,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 131,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 132,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 133,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 134,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 135,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 136,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 137,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 138,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 140,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 142,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 144,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 146,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 148,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 149,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 150,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 151,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 152,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 153,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 154,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 155,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 157,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 159,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 161,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 163,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 165,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 166,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 167,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 168,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 169,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 170,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 171,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 172,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 174,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 176,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 178,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 179,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 180,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 181,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 182,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 183,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 184,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 185,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 187,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 189,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 191,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 192,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 193,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 194,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 195,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 196,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 197,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 198,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 200,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 202,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 204,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 205,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 206,
      "preview": "|  Dietetic Registration | Completion of this 60,000 profession specific or PCE activity awards CPE "
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 207,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 208,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 209,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 210,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 211,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 213,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 215,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 217
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 219,
      "preview": "|  Webinar Topic | CE Credit Deadline*  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 220,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 221,
      "preview": "|  Fluids and Electrolytes | August 30, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 222,
      "preview": "|  Parenteral Nutrition (PN) and Home PN | September 6, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 223,
      "preview": "|  Nutrient Deficiencies and Malnutrition Assessment | September 13, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 224,
      "preview": "|  Enteral Nutrition (EN) and Home EN | September 19, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 225,
      "preview": "|  Enteral Nutrition and Parenteral Nutrition Access | September 27, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 226,
      "preview": "|  Gastrointestinal (GI) Disorders | October 4, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 227,
      "preview": "|  Acid Base | October 10, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 228,
      "preview": "|  Critical Care and Statistics | October 12, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 229,
      "preview": "|  Ethics for the Nutrition Professional | October 17, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 230,
      "preview": "|  Pediatric and Neonatal Nutrition Support | October 19, 2025  |"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 232,
      "preview": "*Please note that CE credit cannot be claimed after the deadline"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 234,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit - Important Information",
      "line": 236
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Please note the following:",
      "line": 238
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 240,
      "preview": "- CE credit CANNOT be claimed for missed webinars. You must attend the live webinar broadcast at the"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 241,
      "preview": "- CE Credit is calculated on a per webinar attended basis. If you miss a webinar, you can still rece"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 242,
      "preview": "- CE credit will be granted for each webinar attended up to a maximum of 15.5 CE credits for the ent"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 243,
      "preview": "- You must complete the evaluation after each webinar to receive CE credit for that webinar."
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 244,
      "preview": "- You must complete the Overall Conference Evaluation to receive your course certificate. This form "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 247
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 249,
      "preview": "Due to Accreditation Council for Pharmacy Education (ACPE) and National Association of Boards of Pha"
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 251,
      "preview": "Pharmacy participants are required to submit their birthdate (MM/DD), submit their NABP ID \\#, and c"
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 253,
      "preview": "ASPEN is not responsible for late or incorrect submissions by the participant."
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 255,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Claim CE Credit",
      "line": 257
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Log into eLearning Center",
      "line": 259
    },
    {
      "type": "text",
      "section": "Log into eLearning Center",
      "line": 261,
      "preview": "Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com."
    },
    {
      "type": "text",
      "section": "Log into eLearning Center",
      "line": 262,
      "preview": "(Your login is the same email and password you use for the main ASPEN website.)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "To Claim CE Credit",
      "line": 264
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 266,
      "preview": "Step 2: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 267,
      "preview": "Step 3: Click \"Live Events\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 268,
      "preview": "Step 4: Find the Nutrition Support Fundamentals Course Summer 2025. Under the course title and dates"
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 270,
      "preview": "Step 5: Click on \"Evaluations\" in the menu under the course title and dates."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 271,
      "preview": "Step 6: Click on the \"Take Evaluation\" button under the appropriate session heading."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 272,
      "preview": "After completing the evaluation, you should see a statement of completion with the date and time. Th"
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 274,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 276
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 277,
      "preview": "How to View CE Credit and Access CE Transcript"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 279,
      "preview": "To View CE Credit"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 280,
      "preview": "Step 1: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 282,
      "preview": "Step 2: Click \"CE Transcript\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 284,
      "preview": "Step 3: Find the Nutrition Support Fundamentals Course Summer 2025 and click on the Course Title. Yo"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 286,
      "content": "![img-1.jpeg](images/9fc704712b53fa33.png)"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 288,
      "preview": "To Access CE Transcript"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 289,
      "preview": "Please note that you will not be able to print your CE transcript until the end of the course. After"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 291,
      "preview": "Complete steps 1-3 above."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 293,
      "preview": "Click on the \"Overall Evaluation\" button at the bottom of the course information and complete the ov"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 295,
      "preview": "A button that says \"Print Transcript\" should appear at the bottom of the course information. Click o"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 297,
      "content": "![img-2.jpeg](images/20935371c9b9dc3f.png)"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 299,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 301
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 303,
      "preview": "Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com. (Your login is the sam"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 305,
      "preview": "Step 2: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 306,
      "preview": "Step 3: Click \"Live Events\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 307,
      "preview": "Step 4: Find Nutrition Support Fundamentals Course Summer 2025. Under the course title and dates, cl"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 309,
      "preview": "Step 5: Click on \"Recordings\" in the menu under the course title and dates."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 310,
      "preview": "Step 6: Find the appropriate webinar session and click on the \"View Archive\" button."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 311,
      "preview": "To listen to the recording, click inside the webinar player."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 312,
      "preview": "To download the recording, click \"Download MP3\" underneath the webinar player on the right side of t"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 314,
      "preview": "To download the handouts, click on the \"Download Handout\" underneath the webinar player on the right"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 315,
      "preview": "*The webinar recording will be available in the eLearning Center within 3 business days following th"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 316,
      "preview": "**If you miss the live webinar broadcast, you can still access the webinar handout and recording in "
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 318,
      "preview": "--- page 7 ---"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 320,
      "content": "![img-3.jpeg](images/46f1c63bd9acccb9.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course",
      "line": 322
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 324
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 326,
      "preview": "**August 6, 2025 \u2022 3:00 \u2013 4:30 PM ET**"
    },
    {
      "type": "image",
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 328,
      "content": "![img-4.jpeg](images/77ccd0a6a1b24197.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Using the Webinar Player",
      "line": 330
    },
    {
      "type": "image",
      "section": "Using the Webinar Player",
      "line": 332,
      "content": "![img-5.jpeg](images/d70217d4692159f6.png)"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 334,
      "preview": "Click on the tabs on the left side of your screen to access the webinar player functions."
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 336,
      "preview": "- **Info Panel**: View session and presenter information"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 337,
      "preview": "- **Chat**: Communicate with other session attendees"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 338,
      "preview": "- **Polling**: Answer polling questions"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 339,
      "preview": "- **Resources**: Download handout and reference material"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 340,
      "preview": "- **Questions**: Submit questions for presenters"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 342,
      "preview": "For technical assistance, click Request Support."
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 344,
      "preview": "--- page 8 ---"
    },
    {
      "type": "image",
      "section": "Using the Webinar Player",
      "line": 346,
      "content": "![img-6.jpeg](images/0016ca21d662da77.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 348
    },
    {
      "type": "text",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 350,
      "preview": "Chief, Clinical Pharmacy Services"
    },
    {
      "type": "text",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 351,
      "preview": "Mississippi Baptist Medical Center"
    },
    {
      "type": "text",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 352,
      "preview": "Clinical Associate Professor"
    },
    {
      "type": "text",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 353,
      "preview": "University of Mississippi School of Pharmacy"
    },
    {
      "type": "text",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 354,
      "preview": "Jackson, Mississippi"
    },
    {
      "type": "image",
      "section": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP, FASPEN",
      "line": 356,
      "content": "![img-7.jpeg](images/9ef5470133ad1ab6.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Disclosures",
      "line": 358
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 360,
      "preview": "- American Regent-Consultant"
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 361,
      "preview": "- B. Braun-Consultant"
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 362,
      "preview": "- Fresenius Kabi-Speaker/Consultant"
    },
    {
      "type": "image",
      "section": "Disclosures",
      "line": 364,
      "content": "![img-8.jpeg](images/d46484661136ed47.png)"
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 366,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Learning Objectives",
      "line": 368
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 370,
      "preview": "- Discuss indications for parenteral nutrition (PN)"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 371,
      "preview": "- Review parenteral nutrition prescription process"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 372,
      "preview": "- Develop a proper plan for PN monitoring and management"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 373,
      "preview": "- Identify issues related to safe practice"
    },
    {
      "type": "image",
      "section": "Learning Objectives",
      "line": 375,
      "content": "![img-9.jpeg](images/2f226aa1f826d8f6.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Nutrition Process",
      "line": 377
    },
    {
      "type": "image",
      "section": "Parenteral Nutrition Process",
      "line": 379,
      "content": "![img-10.jpeg](images/0cc618b5a71c1f57.png)"
    },
    {
      "type": "text",
      "section": "Parenteral Nutrition Process",
      "line": 381,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Nutrition",
      "line": 383
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Peripheral PN",
      "line": 385
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 387,
      "preview": "- Short term"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 388,
      "preview": "- May be limited by venous access"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 389,
      "preview": "- Maximum osmolarity"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 390,
      "preview": "- $900 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 391,
      "preview": "- Dextrose concentration 5-10\\%"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 392,
      "preview": "- Amino acid concentration 3\\%"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 393,
      "preview": "- Large amount of fluids needed to provide nutrition"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 394,
      "preview": "- Not suitable in RF, CHF"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 395,
      "preview": "- Do potential complications outweigh benefits?"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 397,
      "preview": "Central PN"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 399,
      "preview": "- Long term indefinite duration"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 400,
      "preview": "- Infused via CVC"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 401,
      "preview": "- Hyperosmolar solution rapidly diluted"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 402,
      "preview": "- Can be concentrated"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 403,
      "preview": "- Used for many applications"
    },
    {
      "type": "text",
      "section": "Peripheral PN",
      "line": 404,
      "preview": "- Home infusion, ICU"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Indications for PN",
      "line": 407
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 409,
      "preview": "- Contraindication to EN or access"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 410,
      "preview": "- Impaired absorption or loss of nutrients"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 411,
      "preview": "- Mechanical bowel obstruction"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 412,
      "preview": "- Need for bowel rest"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 413,
      "preview": "- Motility disorders"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 414,
      "preview": "- Inability to achieve or maintain enteral access"
    },
    {
      "type": "text",
      "section": "Indications for PN",
      "line": 416,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Criteria",
      "line": 418
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 420,
      "preview": "- Well nourished stable adult - wait 7 days"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 421,
      "preview": "- Nutritionally-at-risk - wait 3-5 days"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 422,
      "preview": "- Baseline moderate or severe malnutrition - as soon as feasible"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 423,
      "preview": "- Delay in those with severe metabolic instability"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 424,
      "preview": "- Address electrolyte abnormalities"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 425,
      "preview": "- Address hypovolemia, shock, hypoxia"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 426,
      "preview": "- CVC available?"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 427,
      "preview": "- Duration of therapy exceeds 5-7 days"
    },
    {
      "type": "text",
      "section": "PN Criteria",
      "line": 429,
      "preview": "Worthington P, Balint J, Bechtold M, etal. When is Parenteral Nutrition Appropriate? JPEN. 2017 Mar;"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "PN Delivery Systems",
      "line": 431
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 433,
      "preview": "- Compounded PN"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 434,
      "preview": "- 2 in 1"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 435,
      "preview": "- Amino acid + Dextrose"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 436,
      "preview": "- Intravenous lipid emulsion (ILE) piggybacked"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 437,
      "preview": "- 12 hour hang time"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 438,
      "preview": "- Improved visual inspection"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 439,
      "preview": "- Filter with 0.2 micron filter and 1.2 micron for ILE"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 440,
      "preview": "- Total Nutrient Admixture (TNA) or 3 in 1"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 441,
      "preview": "- Amino acid + Dextrose + ILE in same bag"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 442,
      "preview": "- Easier for home administration"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 443,
      "preview": "- Filter with 1.2 micron filter"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 444,
      "preview": "- 24 hour hang time"
    },
    {
      "type": "text",
      "section": "PN Delivery Systems",
      "line": 446,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Compounded PN**",
      "line": 448
    },
    {
      "type": "image",
      "section": "**Compounded PN**",
      "line": 450,
      "content": "![img-11.jpeg](images/92907d50d5cd04ed.png)"
    },
    {
      "type": "image",
      "section": "**Compounded PN**",
      "line": 452,
      "content": "![img-12.jpeg](images/2f271c5ba2d9068f.png)"
    },
    {
      "type": "text",
      "section": "**Compounded PN**",
      "line": 454,
      "preview": "2 in 1 PN"
    },
    {
      "type": "text",
      "section": "**Compounded PN**",
      "line": 456,
      "preview": "3 in 1 PN"
    },
    {
      "type": "image",
      "section": "**Compounded PN**",
      "line": 458,
      "content": "![img-13.jpeg](images/c9d82998f0afc111.png)"
    },
    {
      "type": "text",
      "section": "**Compounded PN**",
      "line": 460,
      "preview": "**a** *a**p**e**n* LEADING THE SCIENCE AND PRACTICE OF SURVEYS, NUTRITION *a**s**p**e**n* LEADING TH"
    },
    {
      "type": "text",
      "section": "**Compounded PN**",
      "line": 462,
      "preview": "--- page 13 ---"
    },
    {
      "type": "image",
      "section": "**Compounded PN**",
      "line": 464,
      "content": "![img-14.jpeg](images/231011de97055889.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Carbohydrate Provision",
      "line": 466
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 468,
      "preview": "- Preferred fuel for CNS, blood cells, granulation tissue"
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 469,
      "preview": "- Largest amount of calories in PN from carbohydrates"
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 470,
      "preview": "- Dextrose"
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 471,
      "preview": "- 3.4 kcal/gram"
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 472,
      "preview": "- pH ranging from 3.5 \u2013 6.5"
    },
    {
      "type": "text",
      "section": "Carbohydrate Provision",
      "line": 474,
      "preview": "--- page 14 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Protein Provision",
      "line": 476
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 478,
      "preview": "- Necessary for synthesis of structural protein, growth, enzymatic function"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 479,
      "preview": "- Amino acid solution (crystalline)"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 480,
      "preview": "- 4 kcal/gram"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 481,
      "preview": "- Acetate or chloride load from AA solution"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 482,
      "preview": "- Assumed to be 16% nitrogen"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 483,
      "preview": "- 6.25g protein = 1g nitrogen"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 484,
      "preview": "- Standard 8.5% or 10%"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 485,
      "preview": "- Concentrated 15% or 20%"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 486,
      "preview": "- May benefit volume restricted patients"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 488,
      "preview": "|  Generation of ILE^{1} | Description | Rationale for design | Other potential benefits  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 489,
      "preview": "| --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 490,
      "preview": "|  First | Single-oil formulation using either SO or safflower oil^{2} | Source of EFA and energy | "
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 491,
      "preview": "|  Second | Two-oil formulation including SO and MCT^{6} | Lower SO content | Reducing the \u03c9-6 FA co"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 492,
      "preview": "|   |  |  | More stable ILE product with MCT oil^{17}  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 493,
      "preview": "|   |  |  | MCTs accumulate less in adipose tissues and liver and are cleared faster with minimal pe"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 494,
      "preview": "|   |  |  | MCTs do not produce proinflammatory mediators^{18}  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 495,
      "preview": "|  Third | Two-oil ILE using SO and OO, resulting in a reduced amount of EFA (\u03c9-6 FAs) | Reduce SO c"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 496,
      "preview": "|   |  |  | Oleic acid in OO is not metabolized to mediators of inflammation and immunity  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 497,
      "preview": "|   |  |  | Potentially well suited for patients who are at risk of immune suppression or are immune"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 498,
      "preview": "|  Fourth | Four-oil ILE including SO, MCT, OO, and FO | Designed to include an optimal level of \u03c9-6"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 499,
      "preview": "|   |  |  | FO included for critically ill and surgical patient populations  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 500,
      "preview": "|   |  |  | OO may be beneficial in those with immune disorders  |"
    },
    {
      "type": "table",
      "section": "Protein Provision",
      "line": 501,
      "preview": "|   | FO | Source of FAs and energy in infants and children with IFALD | May reverse IFALD  |"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 503,
      "preview": "Nutr Clin Pract 2020;00:1-14."
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 505,
      "preview": "16"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 507,
      "preview": "LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 509,
      "preview": "Nutr Clin Pract 2020;00:1-14."
    },
    {
      "type": "text",
      "section": "Protein Provision",
      "line": 511,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Fat Provision",
      "line": 513
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 515,
      "preview": "- Maintains cellular membranes, serves as precursor of prostanoids and leukotrienes"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 516,
      "preview": "- Intravenous Lipid Emulsion (ILE)"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 517,
      "preview": "- 10 kcal/gram"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 518,
      "preview": "- Glycerin makes formulation isotonic"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 519,
      "preview": "- Egg phospholipid acts as emulsifier"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 520,
      "preview": "- Contains phosphate $-1.5 \\mathrm{mmol} / 100 \\mathrm{~mL}$"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 521,
      "preview": "- Contain small amounts of vitamin K from soy or olive oil"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 522,
      "preview": "- $10 \\%$ and $20 \\%$ okay to administer via central or peripheral line"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 523,
      "preview": "- Soybean component provides essential fatty acids"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 524,
      "preview": "- Must be infused with 1.2 micron filter"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fat Provision",
      "line": 527
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 529,
      "preview": "$100 \\%$ Soybean based ILE"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 531,
      "preview": "- $10 \\%-1.1 \\mathrm{kcal} / \\mathrm{mL}$"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 532,
      "preview": "- $20 \\%-2 \\mathrm{kcal} / \\mathrm{mL}$"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 533,
      "preview": "- $30 \\%-3 \\mathrm{kcal} / \\mathrm{mL}$"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 534,
      "preview": "- Only for 3-in-1 compounding"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 536,
      "preview": "Clinolipid 20\\%"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 537,
      "preview": "Olive oil"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 538,
      "preview": "Soybean oil"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 540,
      "preview": "- Caution with soybean or egg allergies for 3 ILEs"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 541,
      "preview": "- If no h/o previous ILE or medications suspended in ILE"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 542,
      "preview": "- Test dose may be done $1 \\mathrm{~mL} /$ minute for 30 minutes"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 543,
      "preview": "- If tolerated may advance to prescribed rate"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 544,
      "preview": "- Piggybacked ILE - 12 hour hang time"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 545,
      "preview": "- TNA - 24 hour hang time"
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 547,
      "preview": "--- page 16 ---"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 549,
      "preview": "|   | Implementing (preventing) | Implementing (preventing) | Final (preventing) | Development (prev"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 550,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 551,
      "preview": "|  **Institutions** | Source of calories and essential fatty acids. Prevention of Essential Fatty Ac"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 552,
      "preview": "|  **Chartered Populations** | Adult and Pediatric | Adult | Pediatric | Adult | Adult  |"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 553,
      "preview": "|  **Local populations** | Disturbances of normal fat metabolism such as pathologic hyperlipemia, li"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 554,
      "preview": "|  **Maternal Uses** | - Short term use (1-2 weeks) - Short term use (1-2 weeks) - Short term use (1"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 555,
      "preview": "|  **Timing** | - Adult: < 1g/kg/d for stable/home/long term. - Do not exceed 2.5g/kg/d - ICU: Consi"
    },
    {
      "type": "table",
      "section": "Fat Provision",
      "line": 556,
      "preview": "|  **Dysmenstruation** | - Use a 1.2 micron filter - Use a non-vented infusion set or close vent on "
    },
    {
      "type": "text",
      "section": "Fat Provision",
      "line": 558,
      "preview": "*Special Report*"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 560
    },
    {
      "type": "text",
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 562,
      "preview": "**Patricia Worthington, MSN, RN, CNSC<sup>1,4</sup> ; Kathleen M. Gura, PharmD, BCNSP, FASHP, FASPEN"
    },
    {
      "type": "image",
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 564,
      "content": "![img-15.jpeg](images/2eac702747e0b442.png)"
    },
    {
      "type": "image",
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 566,
      "content": "![img-16.jpeg](images/14fb20167a7a93dc.png)"
    },
    {
      "type": "text",
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 568,
      "preview": "--- page 17 ---"
    },
    {
      "type": "image",
      "section": "**Update on the Use of Filters for Parenteral Nutrition: An ASPEN Position Paper**",
      "line": 570,
      "content": "![img-17.jpeg](images/3d3e380cc1aaf0ca.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Electrolytes",
      "line": 572
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 574,
      "preview": "| Electrolyte | Maintenance | Intake Maximum |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 575,
      "preview": "| :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 576,
      "preview": "| Sodium | $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day | $150 \\mathrm{mEq} / \\mathrm{L}$ <br> (NS concent"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 577,
      "preview": "| Potassium | $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day | $240 \\mathrm{mEq} /$ day |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 578,
      "preview": "| Calcium | $10-15 \\mathrm{mEq} /$ day | $25 \\mathrm{mEq} /$ day |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 579,
      "preview": "| Magnesium | $8-20 \\mathrm{mEq} /$ day | $48 \\mathrm{mEq} /$ day |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 580,
      "preview": "| Phosphate | $20-40 \\mathrm{mmol} /$ day | $60 \\mathrm{mmol} /$ day |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 581,
      "preview": "| Chloride/acetate | Adjust salts to maintain acid base balance |  |"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 583,
      "preview": "Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NCP e"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 585,
      "preview": "--- page 18 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Electrolytes",
      "line": 587
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 589,
      "preview": "| Electrolyte | Salt |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 590,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 591,
      "preview": "| Sodium | Chloride, acetate, phosphate |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 592,
      "preview": "| Potassium | Chloride, acetate, phosphate |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 593,
      "preview": "| Chloride | Sodium, potassium |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 594,
      "preview": "| Acetate | Sodium, potassium |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 595,
      "preview": "| Calcium | Gluconate |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 596,
      "preview": "| Magnesium | Sulfate |"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 598,
      "preview": "- Magnesium Sulfate and Calcium Gluconate are the preferred salts in PN"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 599,
      "preview": "- 3 mmol of sodium phosphate $=4 \\mathrm{mEq}$ sodium"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 600,
      "preview": "- 3 mmol of potassium phosphate $=4.4 \\mathrm{mEq}$ potassium"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 602,
      "preview": "23"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Vitamins",
      "line": 604
    },
    {
      "type": "text",
      "section": "Vitamins",
      "line": 606,
      "preview": "MVI-13 10 mL provides the following"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 608,
      "preview": "| Ascorbic acid | 200 mg | Pyridoxine (B6) | 6 mg |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 609,
      "preview": "| :-- | :-- | :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 610,
      "preview": "| Vitamin A | 3300 IU | Biotin (B7) | 60 mcg |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 611,
      "preview": "| Vitamin D3 | 200 IU | Cyanocobalamin (B12) | 5 mcg |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 612,
      "preview": "| Thiamin (B1) | 6 mg | Vitamin E | 10 IU |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 613,
      "preview": "| Riboflavin (B2) | 3.6 mg | Vitamin K | 150 mcg |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 614,
      "preview": "| Niacinamide (B3) | 40 mg | Folic acid | 600 mcg |"
    },
    {
      "type": "table",
      "section": "Vitamins",
      "line": 615,
      "preview": "| Dexpanthenol (B5) | 15 mg |  |  |"
    },
    {
      "type": "text",
      "section": "Vitamins",
      "line": 617,
      "preview": "--- page 19 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Trace Elements",
      "line": 619
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 621,
      "preview": "|  Trace Element | Deficiency  |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 622,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 623,
      "preview": "|  Zinc | Dermatitis, alopecia, growth retardation, diarrhea  |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 624,
      "preview": "|  Copper | Anemia, depigmentation of hair, neurologic abnormalities  |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 625,
      "preview": "|  Chromium | Glucose intolerance  |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 626,
      "preview": "|  Manganese | Not well documented  |"
    },
    {
      "type": "table",
      "section": "Trace Elements",
      "line": 627,
      "preview": "|  Selenium | Cardiomyopathy  |"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 629,
      "preview": "- Tralament ${ }^{\\text {TM }}$ contains: Zinc 3 mg Copper 0.3 mg Manganese 55 mcg Selenium 60 mcg"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Trace Elements",
      "line": 631
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 633,
      "preview": "- Check for availability of single entity TE"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 634,
      "preview": "- Zinc"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 635,
      "preview": "- Consider additional 10-15 mg/daily"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 636,
      "preview": "- High GI loss, decubitus ulcers"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 637,
      "preview": "- Copper"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 638,
      "preview": "- Eliminated exclusively through bile"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 639,
      "preview": "- Hold or decrease in cholestasis"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 640,
      "preview": "- Chromium"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 641,
      "preview": "- Renally eliminated"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 642,
      "preview": "- Consider holding or decreasing in renal failure"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 643,
      "preview": "- Manganese"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 644,
      "preview": "- Eliminated exclusively through bile"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 645,
      "preview": "- Hold or decrease in cholestasis"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 646,
      "preview": "- Selenium"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 647,
      "preview": "- Consider additional 20-40 mcg/daily"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 648,
      "preview": "- Burns, malabsorptive states, critically ill"
    },
    {
      "type": "text",
      "section": "Trace Elements",
      "line": 650,
      "preview": "--- page 20 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Osmolarity",
      "line": 652
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 654,
      "preview": "- Provides limits for safe administration of peripheral PN"
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 655,
      "preview": "- Peripheral < 900 mOsm/L"
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 656,
      "preview": "- Central > 900 mOsm/L"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "PN Osmolarity",
      "line": 658
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 660,
      "preview": "|  PN Component | mOsm  |"
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 661,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 662,
      "preview": "|  Amino Acids | $1 \\mathrm{~g}=10 \\mathrm{mOsm}$  |"
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 663,
      "preview": "|  Dextrose | $1 \\mathrm{~g}=5 \\mathrm{mOsm}$  |"
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 664,
      "preview": "|  IV Lipid Emulsion | $1 \\mathrm{~g}=0.71 \\mathrm{mOsm}$  |"
    },
    {
      "type": "table",
      "section": "PN Osmolarity",
      "line": 665,
      "preview": "|  Electrolytes | $1 \\mathrm{mEq}=1 \\mathrm{mOsm}$  |"
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 667,
      "preview": "- REMEMBER this is an estimate base on the osmolarity of the PN components"
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 668,
      "preview": "- ILE osmolarity is product dependent"
    },
    {
      "type": "text",
      "section": "PN Osmolarity",
      "line": 670,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Question 1",
      "line": 672
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 674,
      "preview": "1 LPN is compounded with the following content:"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 676,
      "preview": "- Amino acid -60 g"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 677,
      "preview": "- Dextrose - 170 g"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 678,
      "preview": "- 20\\% ILE - 20 g"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 679,
      "preview": "- Electrolytes - 243 mEq"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 681,
      "preview": "What is the estimated osmolarity?"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 682,
      "preview": "a) $1607 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 683,
      "preview": "b) $1707 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 684,
      "preview": "c) $1807 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 685,
      "preview": "d) $1907 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Question 1",
      "line": 687
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 689,
      "preview": "Answer b) $1707 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 691,
      "preview": "Amino acid $60 \\mathrm{~g} \\times 10 \\mathrm{mOsm} / \\mathrm{g}=600 \\mathrm{mOsm}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 692,
      "preview": "Dextrose $170 \\mathrm{~g} \\times 5 \\mathrm{mOsm} / \\mathrm{g}=850 \\mathrm{mOsm}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 693,
      "preview": "ILE $20 \\mathrm{~g} \\times 0.71 \\mathrm{mOsm} / \\mathrm{g}=14.2 \\mathrm{mOsm}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 694,
      "preview": "Electrolytes $243 \\mathrm{mEq} \\times 1 \\mathrm{mOsm} / \\mathrm{mEq}=243 \\mathrm{mOsm}$"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 695,
      "preview": "$600 \\mathrm{mOsm}+850 \\mathrm{mOsm}+14.2 \\mathrm{mOsm}+243 \\mathrm{mOsm}=1707.2 \\mathrm{mOsm} / \\ma"
    },
    {
      "type": "text",
      "section": "Question 1",
      "line": 697,
      "preview": "--- page 22 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Initiating PN",
      "line": 699
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 701,
      "preview": "- Dextrose"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 702,
      "preview": "- Provides $\\sim 50 \\%$ of total calorie intake or $60-85 \\%$ of NPC"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 703,
      "preview": "- Most PN will have goal doses of $150-350 \\mathrm{~g} /$ day"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 704,
      "preview": "- Initiate at roughly $1 / 2$ of goal dextrose"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 705,
      "preview": "- $150-200 \\mathrm{~g} /$ day (general population)"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 706,
      "preview": "- $100-150 \\mathrm{~g} /$ day (h/o DM or stress hyperglycemia)"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 707,
      "preview": "- Advance to goal when BG controlled and electrolytes and acid base status stabilized"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 708,
      "preview": "- Optimal glucose infusion rate $3-5 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ (stressed, hospitaliz"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 709,
      "preview": "- Reserve $6 \\mathrm{mg} / \\mathrm{kg} / \\mathrm{min}$ in non-stressed, looking for weight gain"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 710,
      "preview": "- Maximum $7 \\mathrm{~g} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 712,
      "preview": "31"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Initiating PN",
      "line": 714
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 716,
      "preview": "- Protein"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 717,
      "preview": "- Minimal metabolic effects"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 718,
      "preview": "- Can initiate at goal"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 719,
      "preview": "- Caution with azotemia (BUN > $100 \\mathrm{mg} / \\mathrm{dL}$ )"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 720,
      "preview": "- Fat (ILE)"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 721,
      "preview": "- $15-30 \\%$ total calories"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 722,
      "preview": "- Can estimate dose based on body weight"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 723,
      "preview": "- $<1-2 \\mathrm{~g} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 724,
      "preview": "- Do not exceed $2.5 \\mathrm{~g} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 725,
      "preview": "- To prevent EFAD (100 g weekly SO-ILE)"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 726,
      "preview": "- Give 20\\% ILE 250 mL twice weekly or 500 mL weekly"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 727,
      "preview": "- This is important during shortages"
    },
    {
      "type": "text",
      "section": "Initiating PN",
      "line": 729,
      "preview": "--- page 23 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Question 2",
      "line": 731
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 733,
      "preview": "A 3-in-1 TPN is compounded with the following:"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 735,
      "preview": "- 440 mL of $15 \\%$ Clinisol\u00ae"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 736,
      "preview": "- 340 mL of $70 \\%$ Dextrose"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 737,
      "preview": "- 100 mL of $20 \\%$ ILE"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 739,
      "preview": "How much protein is provided per day?"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 740,
      "preview": "a) 60 grams/day"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 741,
      "preview": "b) 66 grams/day"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 742,
      "preview": "c) 70 grams/day"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 743,
      "preview": "d) 76 grams/day"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Question 2",
      "line": 745
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 747,
      "preview": "Answer b) 66 grams"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 749,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 750,
      "preview": "\\begin{aligned}"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 751,
      "preview": "& \\frac{15 \\mathrm{~g}}{100 \\mathrm{~mL}}=\\frac{\\mathrm{x}(\\mathrm{~g})}{440 \\mathrm{~mL}} \\\\"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 752,
      "preview": "& 100 \\mathrm{x}=15 \\times 440 \\\\"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 753,
      "preview": "& \\mathrm{x}=\\frac{6600}{100} \\\\"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 754,
      "preview": "& \\mathrm{x}=66 \\text { grams }"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 755,
      "preview": "\\end{aligned}"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 756,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "Question 2",
      "line": 758,
      "preview": "--- page 24 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Question 3",
      "line": 760
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 762,
      "preview": "A 3-in-1 TPN is compounded with the following:"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 764,
      "preview": "- 440 mL of $15 \\%$ Clinisol"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 765,
      "preview": "- 340 mL of $70 \\%$ Dextrose"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 766,
      "preview": "- 100 mL of $20 \\%$ ILE"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 768,
      "preview": "How many total calories are provided per day?"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 769,
      "preview": "a) 1153 kcal"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 770,
      "preview": "b) 1173 kcal"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 771,
      "preview": "c) 1273 kcal"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 772,
      "preview": "d) 1373 kcal"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Question 3",
      "line": 774
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 776,
      "preview": "Answer c) 1273 kcal"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 778,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 779,
      "preview": "\\begin{aligned}"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 780,
      "preview": "& 66 \\text { grams Protein } \\times 4 \\mathrm{kcal} / \\mathrm{gram}=264 \\mathrm{kcal} \\\\"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 781,
      "preview": "& \\begin{array}{c}"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 782,
      "preview": "\\frac{70 \\mathrm{~g} \\text { dextrose }}{100 \\mathrm{~mL}}=\\frac{\\mathrm{x}(\\mathrm{~g} \\text { dext"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 783,
      "preview": "100 \\mathrm{x}=23800 \\\\"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 784,
      "preview": "\\mathrm{x}=238 \\mathrm{~g} \\text { dextrose } \\\\"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 785,
      "preview": "238 \\mathrm{~g} \\text { dextrose } \\times 3.4 \\mathrm{kcal} / \\mathrm{gram}=809 \\mathrm{kcal}"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 786,
      "preview": "\\end{array} \\\\"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 787,
      "preview": "& 100 \\mathrm{~mL} \\text { ILE } \\times 2 \\mathrm{kcal} / \\mathrm{mL}=200 \\mathrm{kcal}"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 788,
      "preview": "\\end{aligned}"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 789,
      "preview": "$$"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 791,
      "preview": "264 protein kcal +809 dextrose kcal +200 ILE kcal $=1273$ total daily kcal"
    },
    {
      "type": "text",
      "section": "Question 3",
      "line": 793,
      "preview": "--- page 25 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Administration",
      "line": 795
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 797,
      "preview": "- Initial PN is infused 24 hour (continuous)"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 798,
      "preview": "- When plans move to long term PN cycling is a possibility"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 799,
      "preview": "- 8 - 22 hour infusion"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 800,
      "preview": "- PN is \"cycled down\" based on tolerance"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 801,
      "preview": "- PN is titrated and tapered over 1 - 2 hours before and after infusion"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 802,
      "preview": "- \"ramp up and down\""
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 803,
      "preview": "- Prevents hyper- and hypoglycemia"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 804,
      "preview": "- Cycling improves QOL"
    },
    {
      "type": "text",
      "section": "PN Administration",
      "line": 805,
      "preview": "- May alleviate PNALD"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Monitoring",
      "line": 808
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 810,
      "preview": "- Fluid balance"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 811,
      "preview": "- Daily weights, I/Os"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 812,
      "preview": "- Acid-base status"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 813,
      "preview": "- Visceral proteins?"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 814,
      "preview": "- C-reactive protein"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 815,
      "preview": "- APR that marks inflammation"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 817,
      "preview": "--- page 26 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper",
      "line": 819
    },
    {
      "type": "text",
      "section": "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper",
      "line": 821,
      "preview": "**David C. Evans, MD, FACS, PNS\u00b9; Mark R. Corkins, MD, CNSC, FASPEN, AGAF, FAAP\u00b2; Ainsley Malone, MS"
    },
    {
      "type": "text",
      "section": "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper",
      "line": 823,
      "preview": "**Sarah Miller, PharmD, BCNSP\u00b3; Kris M. Mogensen, MS, RD-AP, LDN, CNSC\u2074**"
    },
    {
      "type": "text",
      "section": "The Use of Visceral Proteins as Nutrition Markers: An ASPEN Position Paper",
      "line": 825,
      "preview": "**Peggi Guenter, PhD, RN, FAAN, FASPEN\u2075; Gordon L. Jensen, MD, PhD\u2076; and the ASPEN Malnutrition Comm"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Executive Summary",
      "line": 827
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 829,
      "preview": "- Serum albumin and prealbumin are not components of currently accepted definitions of malnutrition."
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 830,
      "preview": "- Serum albumin and prealbumin do not serve as valid proxy measures of total body protein or total m"
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 831,
      "preview": "- The serum concentrations of albumin and prealbumin decline in the presence of inflammation, regard"
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 832,
      "preview": "- Serum albumin and prealbumin declines must be recognized as inflammatory markers associated with \""
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 833,
      "preview": "- The role of serum albumin and prealbumin in monitoring delivery and efficacy of nutrition support "
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 835,
      "preview": "Nutr Clin Pract. 2021;36:22-28"
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 837,
      "preview": "**LIFESTYLE OF SURVEYS AND PRACTICE OF SURVEYS**"
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 839,
      "preview": "Nutrition in Clinical Practice Volume 36 Number 1 February 2021 22-28 \u00a9 2020 American Society for Pa"
    },
    {
      "type": "text",
      "section": "Executive Summary",
      "line": 841,
      "preview": "--- page 27 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Monitoring",
      "line": 843
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 845,
      "preview": "- Nitrogen balance"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 846,
      "preview": "- Asses protein requirement and adequacy"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 847,
      "preview": "- Stool and skin losses are estimated to be 2 g nitrogen/day"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 848,
      "preview": "nitrogen balance $=$ nitrogen intake - nitrogen output"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 849,
      "preview": "nitrogen balance $\\left(\\frac{g}{\\text { day }}\\right)=\\left(\\frac{\\text { protein intake }}{6.25}\\r"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Monitoring",
      "line": 852
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 854,
      "preview": "- Indirect calorimetry"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 855,
      "preview": "- RQ is the ratio of $\\mathrm{CO}_{2}$ production to $\\mathrm{O}_{2}$ consumption"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 857,
      "preview": "| Substrate Utilization | RQ |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 858,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 859,
      "preview": "| Ethanol | 0.67 |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 860,
      "preview": "| Fat oxidation | 0.71 |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 861,
      "preview": "| Protein oxidation | 0.82 |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 862,
      "preview": "| Mixed substrate oxidation | 0.85 |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 863,
      "preview": "| Carbohydrate oxidation | 1 |"
    },
    {
      "type": "table",
      "section": "Monitoring",
      "line": 864,
      "preview": "| Lipogenesis | $1-1.2$ |"
    },
    {
      "type": "text",
      "section": "Monitoring",
      "line": 866,
      "preview": "--- page 28 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Laboratory Monitoring",
      "line": 868
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 870,
      "preview": "|  Laboratory | Baseline | Initiation | Critically Ill | Stable Inpatient | Stable Home  |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 871,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 872,
      "preview": "|  Serum chemistry | $\\checkmark$ | Daily $\\times 7$ days | Daily | $1-3$ times per week | Every oth"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 873,
      "preview": "|  Liver function tests | $\\checkmark$ |  | Weekly | Monthly | Same as above  |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 874,
      "preview": "|  CBC with differential | $\\checkmark$ |  | Weekly | Weekly | As needed  |"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 876,
      "preview": "- Chemistry - electrolytes, BUN, SCr, glucose"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 877,
      "preview": "- Corrected Ca++ = Serum Ca + [0.8 x (4 - serum albumin)]"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 878,
      "preview": "- LFT - AST, ALT, total bilirubin, Alk Phos"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 880,
      "preview": "Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NCP e"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Laboratory Monitoring",
      "line": 882
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 884,
      "preview": "|  Laboratory | Baseline | Initiation | Critically Ill | Stable Inpatient | Stable Home  |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 885,
      "preview": "| --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 886,
      "preview": "|  Triglycerides | $\\checkmark$ |  | Weekly | Weekly | Every other week for $1-3$ months then monthl"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 887,
      "preview": "|  Capillary glucose |  | Every 6 hours | Every 4-6 hours | Every 6 hours | As needed  |"
    },
    {
      "type": "table",
      "section": "Laboratory Monitoring",
      "line": 888,
      "preview": "|  CBC with differential | $\\checkmark$ |  | Weekly | Weekly | As needed  |"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 890,
      "preview": "- Target BG $140-180 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 891,
      "preview": "- Can adjust POCT BG based on trends and h/o DM"
    },
    {
      "type": "text",
      "section": "Laboratory Monitoring",
      "line": 893,
      "preview": "--- page 29 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Complications",
      "line": 895
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 897,
      "preview": "- Mechanical"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 898,
      "preview": "- CVC, occlusion, phlebitis, pump failure"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 899,
      "preview": "- Infectious"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 900,
      "preview": "- PN contamination, bacteremia, site infection"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 901,
      "preview": "- Metabolic"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 902,
      "preview": "- Glycemic control"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 903,
      "preview": "- Fluids and electrolytes, acid-base balance"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 904,
      "preview": "- Renal and hepatic issues"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 905,
      "preview": "- Nutrient excess or deficiency"
    },
    {
      "type": "text",
      "section": "PN Complications",
      "line": 906,
      "preview": "- Bone diseases"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Catheter Issues",
      "line": 909
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 911,
      "preview": "- Patency"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 912,
      "preview": "- Ability to infuse or aspirate without resistance"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 913,
      "preview": "- Thrombotic"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 914,
      "preview": "- Intraluminal occlusion or fibrin sleeve"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 915,
      "preview": "- Ensure adequate flushing"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 916,
      "preview": "- Instill anti-thrombotic therapy"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 917,
      "preview": "- Vessel thrombosis"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 918,
      "preview": "- Evaluate for systemic anticoagulation"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 919,
      "preview": "- Can be linked to increased infection risk"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 920,
      "preview": "- Fibrin sheaths promote bacterial adhesion"
    },
    {
      "type": "image",
      "section": "Catheter Issues",
      "line": 921,
      "content": "![img-18.jpeg](images/e57364ee331b74a7.png)"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 923,
      "preview": "--- page 30 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Catheter Issues",
      "line": 925
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 927,
      "preview": "- Non-thrombotic"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 928,
      "preview": "- Mechanical occlusion - kinking of CVC, pinch-off syndrome"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 929,
      "preview": "- PN related"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 930,
      "preview": "- Calcium-phosphate - infuse acidic agent 0.1 N HCl acid"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 931,
      "preview": "- Lipid deposit - infuse ethanol $70 \\%$"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 932,
      "preview": "- Drug related"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 933,
      "preview": "- Acid soluble - 0.1 Normal HCl acid (eg. vancomycin)"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 934,
      "preview": "- Base soluble - sodium bicarbonate $8.4 \\%$ (eg. phenytoin)"
    },
    {
      "type": "image",
      "section": "Catheter Issues",
      "line": 935,
      "content": "![img-19.jpeg](images/f602d62d3b64a89d.png)"
    },
    {
      "type": "text",
      "section": "Catheter Issues",
      "line": 937,
      "preview": "47"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Glycemic Control",
      "line": 939
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 941,
      "preview": "- Target BG - 140 - $180 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 942,
      "preview": "- Initiate PN @ 50\\% of target dextrose"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 943,
      "preview": "- Remove dextrose from maintenance IVF"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 944,
      "preview": "- Pharmacotherapy"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 945,
      "preview": "- Regular insulin added to PN ( 0.1 units/g dextrose)"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 946,
      "preview": "- Regular correctional ISS (q6h to q4h)"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 947,
      "preview": "- Review response to correctional and add back to next PN"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 948,
      "preview": "- Regular insulin infusion (preferred in critically ill)"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 949,
      "preview": "- Modify calories"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 950,
      "preview": "- Increase fat calories and decrease dextrose calories"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 951,
      "preview": "- Reassess patient for caloric needs"
    },
    {
      "type": "text",
      "section": "Glycemic Control",
      "line": 953,
      "preview": "--- page 31 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Refeeding Syndrome",
      "line": 955
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 957,
      "preview": "- Can occur with any dextrose source"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 958,
      "preview": "- PN, EN, PO, dextrose containing base fluid"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 959,
      "preview": "- Carbohydrate introduction causes"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 960,
      "preview": "- Insulin secretion"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 961,
      "preview": "- Electrolyte shifting"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 962,
      "preview": "- Thiamine depletion"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 963,
      "preview": "- At risk patients"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 964,
      "preview": "- Anorexia, alcoholism, chronic diseases associated with malnutrition"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 965,
      "preview": "- Correct electrolyte derangements"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 966,
      "preview": "- Add Thiamine 100 mg daily for $5-10$ days"
    },
    {
      "type": "text",
      "section": "Refeeding Syndrome",
      "line": 968,
      "preview": "Consensus Recommendation"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 970
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 972,
      "preview": "Joshua S. V. da Silva, DO ${ }^{1}$; David S. Seres, MD, ScM, PNS, FASPEN ${ }^{2}$; Kim Sabino, MS,"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 974,
      "preview": "--- page 32 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 976
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 978,
      "preview": "Table 3. ASPEN Consensus Criteria for Identifying Adult Patients at Risk for Refeeding Syndrome. ${ "
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 980,
      "preview": "|  | Moderate Risk: 2 Risk Criteria Needed | Significant Risk: 1 Risk Criterion Needed |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 981,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 982,
      "preview": "| BMI | $16-18.5 \\mathrm{~kg} / \\mathrm{m}^{2}$ | $<16 \\mathrm{~kg} / \\mathrm{m}^{2}$ |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 983,
      "preview": "| Weight loss | $5 \\%$ in 1 month | $7.5 \\%$ in 3 months or $>10 \\%$ in 6 months |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 984,
      "preview": "| Caloric intake | None or negligible oral intake for 5-6 days OR $<75 \\%$ of estimated energy requi"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 985,
      "preview": "| Abnormal prefeeding potassium, phosphorus, or magnesium serum concentrations ${ }^{a}$ <br> Loss o"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 987,
      "preview": "[^0]Table 6. ASPEN Consensus Recommendations for Avoidance and Treatment of RS in At-Risk Adults."
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 989,
      "preview": "| Aspect of Care | Recommendations |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 990,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 991,
      "preview": "| Initiation of calories | - Initiate with $100-150 \\mathrm{~g}$ of dextrose or $10-20 \\mathrm{~kg} "
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 992,
      "preview": "| Fluid restriction | - No recommendation. |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 993,
      "preview": "| Sodium restriction | - No recommendation. |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 994,
      "preview": "| Protein restriction | - Check serum potassium, magnesium, and phosphorus before initiation of nutr"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 995,
      "preview": "| Electrolytes | - Monitor every 12 hours for the first 3 days in high-risk patients. May be more fr"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 996,
      "preview": "| Thiamin and multivitamins | - Supplement thiamin 100 mg before feeding or before initiating dextro"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 998,
      "preview": "[^1]"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 999,
      "preview": "[^0]:    ASPEN, American Society for Parenteral and Enteral Nutrition; IV, intravenous; MVI, multivi"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 1001,
      "preview": "[^1]:    ASPEN, American Society for Parenteral and Enteral Nutrition; IV, intravenous; MVI, multivi"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Criteria for Identifying at Risk Patients",
      "line": 1003,
      "preview": "--- page 33 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hepatobiliary Complications",
      "line": 1005
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1007,
      "preview": "- Steatosis"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1008,
      "preview": "- Hepatic fat accumulation"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1009,
      "preview": "- Predominantly in adults"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1010,
      "preview": "- Modest elevations in transaminases within 2 weeks of PN therapy"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1011,
      "preview": "- Transaminases normalize with D/C of PN"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1012,
      "preview": "- Complication of overfeeding"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1013,
      "preview": "- Cholestasis"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1014,
      "preview": "- Impaired bile secretion or biliary obstruction"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1015,
      "preview": "- Elevation of alk phos, GGT, and conjugated (direct) bilirubin"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1016,
      "preview": "- Elevated total bilirubin $>2 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1017,
      "preview": "- Gallbladder sludge/stones"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1018,
      "preview": "- Related to lack of enteral stimulation"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complications",
      "line": 1019,
      "preview": "- Related to duration of PN therapy"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1022
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1024,
      "preview": "- Energy"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1025,
      "preview": "- Overfeeding promotes hepatic fat deposition"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1026,
      "preview": "- Carbohydrates"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1027,
      "preview": "- Balanced PN formulation"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1028,
      "preview": "- ILE"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1029,
      "preview": "- High concentrations of omega-6 fatty acids and phytosterols"
    },
    {
      "type": "text",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1031,
      "preview": "--- page 34 ---"
    },
    {
      "type": "image",
      "section": "Hepatobiliary Complication Risk Factors",
      "line": 1033,
      "content": "![img-20.jpeg](images/5cf7e3e64f2a9566.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Managing PN Associated Liver Complications",
      "line": 1035
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1037,
      "preview": "- **Rule out non-PN factors**"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1038,
      "preview": "- Medications, herbal supplements, biliary obstruction, hepatitis"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1039,
      "preview": "- **Consider PN modifications**"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1040,
      "preview": "- Decrease dextrose, decrease ILE, balanced calories, cycle PN infusion"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1041,
      "preview": "- **Maximize enteral intake**"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1042,
      "preview": "- Encourage oral intake if possible, slow rate EN"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1043,
      "preview": "- **Treat SIBO**"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1044,
      "preview": "- Enteral antibiotics"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1045,
      "preview": "- **Pharmacotherapy**"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1046,
      "preview": "- Ursodiol, antihistamines"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1047,
      "preview": "- **Intestinal transplantation**"
    },
    {
      "type": "image",
      "section": "Managing PN Associated Liver Complications",
      "line": 1049,
      "content": "![img-21.jpeg](images/f3fdab93d14748a4.png)"
    },
    {
      "type": "text",
      "section": "Managing PN Associated Liver Complications",
      "line": 1051,
      "preview": "--- page 35 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypertriglyceridemia",
      "line": 1053
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1055,
      "preview": "- Can occur with dextrose overfeeding or rapid ILE administration rates"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1056,
      "preview": "- Review risk factors increasing intolerance"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1057,
      "preview": "- Disease states, medications"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1058,
      "preview": "- Hold ILE if Serum TG > $400 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1059,
      "preview": "- Fat intolerant - reduce ILE"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1060,
      "preview": "- $<30 \\%$ of total calories or $1 \\mathrm{~g} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Hypertriglyceridemia",
      "line": 1061,
      "preview": "- Can administer twice weekly"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1064
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1066,
      "preview": "- At risk patients"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1067,
      "preview": "- ILE free PN > 2 - 4 weeks"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1068,
      "preview": "- Poor nutritional status"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1069,
      "preview": "- Manifestations"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1070,
      "preview": "- Scaly dermatitis, alopecia, poor wound healing, thrombocytopenia"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1071,
      "preview": "- Triene to tetraene ratio of more than 0.2"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1072,
      "preview": "- How to avoid"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1073,
      "preview": "- $1-2 \\%$ of energy should be from linoleic acid"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1074,
      "preview": "- $0.5 \\%$ of energy should be from linolenic acid"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1075,
      "preview": "- 20\\% SO ILE 250 mL twice a week"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1076,
      "preview": "- Trial topical safflower oil in those intolerant to ILE"
    },
    {
      "type": "text",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1078,
      "preview": "--- page 36 ---"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1080,
      "preview": "|  TABLE 2. CALCULATED MINIMUM ILE DAILY DOSE TO MEET 2\\% OF TOTAL KCAL FROM LA ${ }^{2,3}$ |  |  | "
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1081,
      "preview": "| --- | --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1082,
      "preview": "|  Daily total caloric dose | Daily dose SO-ILE (20\\%) |  | Daily dose SO,MCT, OO,FO-ILE (20\\%) |  |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1083,
      "preview": "|  kcal | $\\mathrm{mL}^{*}$ | g | $\\mathrm{mL}^{*}$ | g | $\\mathrm{mL}^{*}$ | g  |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1084,
      "preview": "|  1000 | 20.4 | 4.1 | 62.9 | 12.6 | 61.5 | 12.3  |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1085,
      "preview": "|  1500 | 30.6 | 6.1 | 94.3 | 18.9 | 92.2 | 18.4  |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1086,
      "preview": "|  2000 | 40.8 | 8.2 | 125.7 | 25.1 | 122.9 | 24.6  |"
    },
    {
      "type": "table",
      "section": "Essential Fatty Acid Deficiency (EFAD)",
      "line": 1087,
      "preview": "|  Daily dose, \\% total kcal to meet $\\geq 2 \\%$ of total kcal from LA | $\\geq 4.1 \\%$ |  | $\\geq 12"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Metabolic Bone Disease",
      "line": 1089
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1091,
      "preview": "- Osteoporosis"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1092,
      "preview": "- Reported in 67\\% of long term PN due to intestinal failure"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1093,
      "preview": "- Osteomalacia"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1094,
      "preview": "- Laboratory monitoring"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1095,
      "preview": "- $\\mathrm{Ca}++$, PTH, urine $\\mathrm{Ca}++$, alkaline phosphatase"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1096,
      "preview": "- Risk factors"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1097,
      "preview": "- Malabsorptive disorders, immobility"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1098,
      "preview": "- Preventing and treating osteoporosis in long term PN"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1099,
      "preview": "- Evaluate protein, phosphorus, calcium, sodium dosing"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1100,
      "preview": "- Treat chronic metabolic acidosis"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1101,
      "preview": "- Maintain $\\mathrm{Mg}++$ and copper intake"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1102,
      "preview": "- Minimize aluminum contamination"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1103,
      "preview": "- Encourage weight bearing exercise"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1104,
      "preview": "- Reduce caffeine and limit alcohol intake"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1106,
      "preview": "--- page 37 ---"
    },
    {
      "type": "image",
      "section": "Metabolic Bone Disease",
      "line": 1108,
      "content": "![img-22.jpeg](images/987e7b5014e6eddb.png)"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1110,
      "preview": "61"
    },
    {
      "type": "image",
      "section": "Metabolic Bone Disease",
      "line": 1112,
      "content": "![img-23.jpeg](images/0508f81bba3d4a50.png)"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1114,
      "preview": "62"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1116,
      "preview": "**LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION**"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1118,
      "preview": "*Landscape: Science for Parenthesis and Critical Nutrition*"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1120,
      "preview": "--- page 38 ---"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1122,
      "preview": "Table 10.1. Common Indications for Home Parenteral Nutrition. ${ }^{2,3,36}$"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1124,
      "preview": "- Short bowel syndrome"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1125,
      "preview": "- Crohn's disease"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1126,
      "preview": "- Intestinal motility disorders"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1127,
      "preview": "- Chronic bowel obstruction due to benign adhesions or strictures"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1128,
      "preview": "- Radiation enteritis"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1129,
      "preview": "- Malabsorptive disorders"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1130,
      "preview": "- Intestinal and pancreatic fistula"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1131,
      "preview": "- Gastrointestinal malignancy"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1132,
      "preview": "- Malignant bowel obstruction, carcinomatosis"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1133,
      "preview": "- Complications of bariatric surgery"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1134,
      "preview": "- Gastroschisis"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1135,
      "preview": "- Long-segment Hirschsprung's disease"
    },
    {
      "type": "text",
      "section": "Metabolic Bone Disease",
      "line": 1137,
      "preview": "Reprinted from Worthington P, Balint J, Bechtold M et al. When is parenteral nutrition appropriate? "
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Medicare Coverage for Home PN",
      "line": 1139
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1141,
      "preview": "- September 2021 new Local Coverage Determination (LCD)"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1142,
      "preview": "- Prosthetic Device Benefit within the Durable Medical Equipment benefit"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1143,
      "preview": "- PN is covered for beneficiaries who qualify under the Prosthetic Device Benefit defined in the Med"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1145,
      "preview": "--- page 39 ---"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1147,
      "preview": "|  Considerations | Yes | No  |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1148,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1149,
      "preview": "|  1. Does the patient require home PN for a long and indefinite duration? |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1150,
      "preview": "|  Has this been documented clearly in the medical record by the treating practitioner prior to disc"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1151,
      "preview": "|  2. Daily PN is considered reasonable and necessary for a patient with severe pathology of the ali"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1152,
      "preview": "|  Does the medical record provide clear documentation that supports this? |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1153,
      "preview": "|  3. Has the treating practitioner documented in the medical record that enteral nutrition has been"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1154,
      "preview": "|  4. Does the home PN prescription provide 20\u201335 calories/kg/day? |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1155,
      "preview": "|  If NO: has the treating practitioner documented in the medical record the medical necessity for a"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1156,
      "preview": "|  5. Does the home PN prescription provide 0.8\u20132.0 gm/kg/day of protein, dextrose concentration abo"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1157,
      "preview": "|  If NO: has the treating practitioner documented the medical necessity for protein orders outside "
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1159,
      "preview": "**Table 2. Sample Medicare PN Qualifying Checklist \u2013 PN LCD Effective September 5, 2021**"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1161,
      "preview": "**DOI: 10.1002/ncp.10861**"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1163,
      "preview": "**CONSENSUS STATEMENT**"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1165,
      "preview": "**Safe care transitions for patients receiving parenteral nutrition**"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1167,
      "preview": "**Stephen C. Adams MS, RPh^{1}** | **Kathleen M. Gura PharmD^{2}** | **David S. Seres MD, ScM^{3}** "
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1169,
      "preview": "--- page 40 ---"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1171,
      "preview": "|   | Day of"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1172,
      "preview": "Admission | Subsequent"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1173,
      "preview": "days | Day of"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1174,
      "preview": "Discharge | Post"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1175,
      "preview": "discharge  |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1176,
      "preview": "| --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1177,
      "preview": "|  Indication for PN"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1178,
      "preview": "PN coverage/reimbursement is verified"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1179,
      "preview": "Patient is determined to be stable for discharge"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1180,
      "preview": "Decision to cycle PN or not is determined and"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1181,
      "preview": "communicated"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1182,
      "preview": "Patient is deemed appropriate candidate for PN"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1183,
      "preview": "Appropriate IV access is in place"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1184,
      "preview": "Goals of PN therapy is identified |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1185,
      "preview": "|  Identification of caregiver(s)"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1186,
      "preview": "Contact information for caregiver(s) is"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1187,
      "preview": "recorded"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1188,
      "preview": "Caregiver(s) is determined to be able/willing to"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1189,
      "preview": "manage PN"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1190,
      "preview": "Home environment is assessed to be safe |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1191,
      "preview": "|  PN formula and other home IV therapies"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1192,
      "preview": "PN formula is transmitted to home infusion"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1193,
      "preview": "provider, home health"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1194,
      "preview": "Orders are received for other home infusion"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1195,
      "preview": "therapies |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1196,
      "preview": "|  Medication safety"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1197,
      "preview": "Current medications are reviewed, updated,"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1198,
      "preview": "and documented"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1199,
      "preview": "Allergies are reviewed, updated and"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1200,
      "preview": "documented |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1201,
      "preview": "|  Follow up"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1202,
      "preview": "Physician/service following patient identified"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1203,
      "preview": "and documented"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1204,
      "preview": "Labs, including long-term micronutrient"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1205,
      "preview": "assessments, are ordered"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1206,
      "preview": "Discharge summary is forwarded to primary"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1207,
      "preview": "care provider"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1208,
      "preview": "Follow up appointments with following |  |  |  |   |"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1210,
      "preview": "Nutr Clin Pract. 2022;37:493-508"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1212,
      "preview": "67"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1214,
      "preview": "|  Home Care / Alternate Site Care"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1215,
      "preview": "Home care infusion provider is identified"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1216,
      "preview": "Home health agency is identified"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1217,
      "preview": "Patient information is transmitted to home care"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1218,
      "preview": "infusion provider, home health agency |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1219,
      "preview": "| --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1220,
      "preview": "|  Education"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1221,
      "preview": "Catheter care and management of"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1222,
      "preview": "complications are reviewed and"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1223,
      "preview": "understanding is demonstrated"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1224,
      "preview": "Details of PN administration are reviewed and"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1225,
      "preview": "understanding is demonstrated"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1226,
      "preview": "Considerations for travel while on PN are"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1227,
      "preview": "reviewed and understanding is"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1228,
      "preview": "demonstrated"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1229,
      "preview": "Monitoring complications of PN are reviewed"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1230,
      "preview": "and understanding is demonstrated"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1231,
      "preview": "Monitoring of fluid intake and losses are"
    },
    {
      "type": "table",
      "section": "Medicare Coverage for Home PN",
      "line": 1232,
      "preview": "reviewed and understanding demonstrated |  |  |  |   |"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1234,
      "preview": "Nutr Clin Pract. 2022;37:493-508"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1236,
      "preview": "L040146 THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1238,
      "preview": "Nutr Clin Pract. 2022;37:493-508"
    },
    {
      "type": "text",
      "section": "Medicare Coverage for Home PN",
      "line": 1240,
      "preview": "--- page 41 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "HPN - Facilitating Discharge",
      "line": 1242
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1244,
      "preview": "- Obtain diagnostic testing and procedures, verify insurance"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1245,
      "preview": "- Establish long-term vascular access"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1246,
      "preview": "- Establish tolerated PN formula"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1247,
      "preview": "- Assess patient"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1248,
      "preview": "- Activities of daily living, caregiver, home setting, determine patient buy-in"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1249,
      "preview": "- Begin patient education"
    },
    {
      "type": "text",
      "section": "HPN - Facilitating Discharge",
      "line": 1250,
      "preview": "- Identify outpatient management"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "HPN - Home Evaluation",
      "line": 1253
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1255,
      "preview": "- Is home accessible to home health provider?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1256,
      "preview": "- Is environment clean with reliable utilities?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1257,
      "preview": "- Can patient move around home safely?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1258,
      "preview": "- Is the patient willing to learn operation of equipment?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1259,
      "preview": "- Is the caregiver willing to provide additional assistance?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1260,
      "preview": "- Is the patient and caregiver willing to learn problems and willing to contact appropriate services"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1261,
      "preview": "- Is laboratory monitoring available as needed to prevent complications?"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1263,
      "preview": "--- page 42 ---"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1265,
      "preview": "Table 4.1. Clinical Conditions Warranting Cautious Initiation of Parenteral Nutrition in Adults. ${ "
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1267,
      "preview": "| Conditions | Suggested Criteria |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1268,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1269,
      "preview": "| Hyperglycemia | Glucose greater than $180 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1270,
      "preview": "| Azotemia | Blood urea nitrogen greater than $100 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1271,
      "preview": "| Hypertriglyceridemia | Serum triglycerides greater than $200 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1272,
      "preview": "| Hyponatremia | Serum sodium less than $130 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1273,
      "preview": "| Hypernatremia | Serum sodium greater than $150 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1274,
      "preview": "| Hypokalemia | Serum potassium less than $3 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1275,
      "preview": "| Hypomagnesemia | Serum magnesium less than $1.3 \\mathrm{mEq} / \\mathrm{L}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1276,
      "preview": "| Hypocalcemia | Ionized calcium less than $4.5 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1277,
      "preview": "| Hypophosphatemia | Serum phosphorus less than $2 \\mathrm{mg} / \\mathrm{dL}$ |"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1279,
      "preview": "Table 13.2. Laboratory Monitoring During PN (Adult and Pediatric). ${ }^{1,14,17,18}$"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1281,
      "preview": "| Parameter | Acute Care PN |  |  | Long-Term PN |  |  |  |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1282,
      "preview": "| :--: | :--: | :--: | :--: | :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1283,
      "preview": "|  | Baseline | Days 1-7 | Ongoing, Stable | Initial, <br> Postdischarge | Weeks 1-4 <br> (or Until "
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1284,
      "preview": "| Glucose, BUN, creatinine, electrolytes, calcium, magnesium, phosphorus | $\\checkmark$ | Daily $>3$"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1285,
      "preview": "| CBC with differential | $\\checkmark$ | Daily $>3$ or until stable | $1-2 \\times / w k$ | $\\checkma"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1286,
      "preview": "| Total bilirubin, direct bilirubin, AP, AST, ALT, | $\\checkmark$ |  | Weekly | $\\checkmark$ |  |  |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1287,
      "preview": "| PTT, PT, INR | $\\checkmark$ |  | Weekly |  |  |  | Monthly |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1288,
      "preview": "| Triglyceride level | $\\checkmark$ | Pediatric: daily until stable then weekly | Weekly | $\\checkma"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1289,
      "preview": "| Serum proteins (to monitor inflammation) | $\\checkmark$ |  | Weekly | $\\checkmark$ |  |  | Monthly"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1290,
      "preview": "| Iron indices |  |  | As clinically indicated |  |  | $\\checkmark$ | Every 3-6 mo |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1291,
      "preview": "| Zinc, selenium, manganese, copper, chromium |  |  | As clinically indicated |  |  | $\\checkmark$ |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1292,
      "preview": "| Vitamin A, 25-OH vitamin D, vitamin E |  |  | As clinically indicated |  |  | $\\checkmark$ | Every"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1293,
      "preview": "| Vitamin B ${ }_{12}$ and folate |  |  | As clinically indicated |  |  | $\\checkmark$ | Every 6-12 "
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1294,
      "preview": "| TSH |  |  |  | As indicated |  |  | Every 12 mo |"
    },
    {
      "type": "table",
      "section": "HPN - Home Evaluation",
      "line": 1295,
      "preview": "| Carnitine |  |  | No guideline for adults |  |  | $\\checkmark$ Pediatric patients | Every 3-12 mo "
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1297,
      "preview": "ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; BUN, blood"
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1299,
      "preview": "Reprinted from Worthington P, Balint J, Bechtold M et al. When is parenteral nutrition appropriate? "
    },
    {
      "type": "text",
      "section": "HPN - Home Evaluation",
      "line": 1301,
      "preview": "--- page 43 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Errors",
      "line": 1303
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1305,
      "preview": "- Two deaths from Ca/Phos precipitate"
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1306,
      "preview": "- Death from HPN patient receiving PN with final dextrose concentration of 50%"
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1307,
      "preview": "- Infant fatally overdosed with dextrose"
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1308,
      "preview": "- Infant fatally under dosed with dextrose"
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1309,
      "preview": "- Irreversible neonate brain damage from PN with no dextrose"
    },
    {
      "type": "text",
      "section": "PN Errors",
      "line": 1310,
      "preview": "- Iron overload and liver toxicity in child receiving iron dextran in PN"
    },
    {
      "type": "image",
      "section": "PN Errors",
      "line": 1312,
      "content": "![img-24.jpeg](images/4fc487ad1f0ecbb9.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1314
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1316,
      "preview": "|  Severity | Description  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1317,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1318,
      "preview": "|  A | Circumstances or events that have the capacity to cause error  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1319,
      "preview": "|   | An Error occurred:  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1320,
      "preview": "|  B | Did not reach the patient  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1321,
      "preview": "|  C | Reached the patient but no resulted in no harm  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1322,
      "preview": "|  D | Required monitoring to confirm that it resulted in no harm and/or required intervention to pr"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1323,
      "preview": "|  E | May have contributed to or resulted in temporary harm or required intervention  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1324,
      "preview": "|  F | Contributed to or resulted in temporary harm and required initial or prolonged hospitalizatio"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1325,
      "preview": "|  G | Contributed to or resulted in permanent harm  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1326,
      "preview": "|  H | Intervention required to sustain life  |"
    },
    {
      "type": "table",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1327,
      "preview": "|  I | Resulted in patient death  |"
    },
    {
      "type": "text",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1329,
      "preview": "National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP)"
    },
    {
      "type": "text",
      "section": "Med-MARX\u00ae Database Severity Scale",
      "line": 1331,
      "preview": "--- page 44 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1333
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1335,
      "preview": "|  Node | Severity, N"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1336,
      "preview": "A-D | Severity, N"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1337,
      "preview": "E-E | Type  |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1338,
      "preview": "| --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1339,
      "preview": "|  Ordering | 472 | 8 | Improper dose, omission of dose  |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1340,
      "preview": "|  Transcribing | 360 | 3 | Omission of dose, prepared incorrectly  |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1341,
      "preview": "|  Compounding | 90 | 1 | Deteriorated product, omission  |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1342,
      "preview": "|  Administration | 487 | 10 | Expired drug, deteriorated product, omission  |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1343,
      "preview": "|  Ingredient |  |  |   |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1344,
      "preview": "|  Dextrose | 21 | 3 |   |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1345,
      "preview": "|  Fat Emulsion | 254 | 3 |   |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1346,
      "preview": "|  Electrolyte | 92 | 2 |   |"
    },
    {
      "type": "table",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1347,
      "preview": "|  Other | 74 | $5^{*}$ | *Preparation, administration, ordering and administration  |"
    },
    {
      "type": "text",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1349,
      "preview": "*Insulin was the most frequent in the 'Other' category related to more harmful events."
    },
    {
      "type": "text",
      "section": "PN Errors Reported to Med-MARX\u00ae by Node and Ingredient",
      "line": 1351,
      "preview": "Story MA et al. Nutr Clin Pract 31(2);211, 2016"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Stability",
      "line": 1353
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1355,
      "preview": "- The degradation of nutritional components that change their original characteristics."
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1356,
      "preview": "- Also, additives maintaining chemical integrity and pharmacologic activity."
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1357,
      "preview": "- Maillard reaction - brown discoloration"
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1358,
      "preview": "- Photodegradation"
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1359,
      "preview": "- Vitamins"
    },
    {
      "type": "text",
      "section": "Stability",
      "line": 1361,
      "preview": "--- page 45 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "TNA Stability",
      "line": 1363
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1365,
      "preview": "The following will compromise TNA stability."
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1367,
      "preview": "Amino Acids"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1369,
      "preview": "- Final concentration < 4\\%"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1371,
      "preview": "Dextrose"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1373,
      "preview": "- Final concentration < 10\\%"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1375,
      "preview": "ILE"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1377,
      "preview": "- Final concentration < 2\\%"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1379,
      "preview": "High cation concentrations"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1381,
      "preview": "- More than $20 \\mathrm{mEq} / \\mathrm{L}$ of divalent cations $(\\mathrm{Ca}++$, Mg++)"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1382,
      "preview": "- Addition of iron dextran"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1384,
      "preview": "Admixture of dextrose with ILE"
    },
    {
      "type": "text",
      "section": "TNA Stability",
      "line": 1385,
      "preview": "before adding amino acids"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Stability of ILE and TNA",
      "line": 1387
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1389,
      "preview": "- ILE consists of interior oil phase dispersed in external water phase"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1390,
      "preview": "- There is a negative charge on the surface of the fat droplet"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1391,
      "preview": "- When the charge becomes less negative, fat globules form that can lodge in the pulmonary vasculatu"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1392,
      "preview": "- $\\mathrm{pH} 6-9$ is most favorable"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1393,
      "preview": "- When pH is $<5$ or $>10$ this can cause cracking"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1394,
      "preview": "- Monitor crystalline amino acid solution use"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1395,
      "preview": "- Do not add concentrated dextrose directly to ILE"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1396,
      "preview": "- Combine dextrose with amino acid first"
    },
    {
      "type": "text",
      "section": "Stability of ILE and TNA",
      "line": 1398,
      "preview": "--- page 46 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Compatibility",
      "line": 1400
    },
    {
      "type": "text",
      "section": "Compatibility",
      "line": 1402,
      "preview": "- Involved the formation of precipitates"
    },
    {
      "type": "text",
      "section": "Compatibility",
      "line": 1403,
      "preview": "- Most studies evaluate only physical compatibility"
    },
    {
      "type": "text",
      "section": "Compatibility",
      "line": 1404,
      "preview": "- Review physical compatibility charts (Y-site)"
    },
    {
      "type": "text",
      "section": "Compatibility",
      "line": 1405,
      "preview": "- This does not mean a medication can be added to PN"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Calcium and Phosphorus Stability",
      "line": 1408
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1410,
      "preview": "- Lower pH favors the more soluble monobasic calcium phosphate"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1411,
      "preview": "- Calcium gluconate preferred"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1412,
      "preview": "- L-cysteine can decrease pH"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1413,
      "preview": "- Minimize large calcium doses"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1414,
      "preview": "- Confirm doses > 2 times RDA"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1415,
      "preview": "- Hypoalbuminemia, fluid status, acid-base status"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1416,
      "preview": "- Add phosphate first, add calcium last"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1417,
      "preview": "- Store refrigerated"
    },
    {
      "type": "text",
      "section": "Calcium and Phosphorus Stability",
      "line": 1419,
      "preview": "--- page 47 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1421
    },
    {
      "type": "table",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1423,
      "preview": "Joseph I. Boullata PharmD, RPh ${ }^{1}$ | Genene Salman PharmD ${ }^{2}$ | Jay M. Mirtallo MS ${ }^"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1425,
      "preview": "Nutr Clin Pract. 2024;1-14."
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1427,
      "preview": "TABLE 1 Examples of concentration limits."
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1428,
      "preview": "To avoid TNA instability"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1429,
      "preview": "Example $1^{25}$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1430,
      "preview": "PN component product Concentration"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1431,
      "preview": "Amino acids injection (Aminosyn II 15\\%) $4 \\%-7 \\%$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1432,
      "preview": "Dextrose (dextrose $70 \\%$ ) $10 \\%-20 \\%$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1433,
      "preview": "ILE (Liposyn III ${ }^{a} 20 \\%$ ) $2 \\%-5 \\%$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1434,
      "preview": "Divalent cations (sum of calcium and magnesium) ${ }^{b} \\quad 4-20 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1435,
      "preview": "Monovalent cations (sum of sodium and potassium) ${ }^{c} \\quad 0-150 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1436,
      "preview": "Phosphate (as sodium and potassium) $15 \\mathrm{mmol} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1438,
      "preview": "Nutr Clin Pract. 2024;1-14."
    },
    {
      "type": "text",
      "section": "Parenteral nutrition compatibility and stability: Practical considerations",
      "line": 1440,
      "preview": "--- page 48 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Ca-Phos Solubility Curve",
      "line": 1442
    },
    {
      "type": "text",
      "section": "Ca-Phos Solubility Curve",
      "line": 1444,
      "preview": "Figure 1. Composite curve for compatibility of calcium (as gluconate) with phosphates at $20-25^{\\ci"
    },
    {
      "type": "image",
      "section": "Ca-Phos Solubility Curve",
      "line": 1445,
      "content": "![img-25.jpeg](images/d661fe752daa890c.png)"
    },
    {
      "type": "text",
      "section": "Ca-Phos Solubility Curve",
      "line": 1447,
      "preview": "Newton D, Driscoll D. Calcium and phosphate compatibility: Revisited again. AJHP. 2008; 65:73-80."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Visual Inspection",
      "line": 1449
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1451,
      "preview": "- 2 in 1 PN"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1452,
      "preview": "- Able to see solid precipitates"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1453,
      "preview": "- 3 in 1 PN"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1454,
      "preview": "- Cracking"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1455,
      "preview": "- Creaming"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1456,
      "preview": "- Coalescence"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1457,
      "preview": "- Aggregation"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1459,
      "preview": "--- page 49 ---"
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1461,
      "preview": "|  Phase of Destabilization | Definition | Visual appearance | Consequences  |"
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1462,
      "preview": "| --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1463,
      "preview": "|  Aggregation (flocculation) | Process by which dispersed droplets come together but do not fuse | "
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1464,
      "preview": "|  Creaming | Formation of a layer of aggregates at the emulsion surface | A translucent phase appea"
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1465,
      "preview": "|  Coalescence | A fusion of droplets leading to fewer droplets and increase in droplet size | Conta"
    },
    {
      "type": "table",
      "section": "Visual Inspection",
      "line": 1466,
      "preview": "|  Oiling out (crack) | Coalescence continues to a point of complete separation\u2014oily layer is seen a"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1468,
      "preview": "Nutr Clin Pract 2020;00:1-14"
    },
    {
      "type": "image",
      "section": "Visual Inspection",
      "line": 1470,
      "content": "![img-26.jpeg](images/661bb07e3fab56ff.png)"
    },
    {
      "type": "text",
      "section": "Visual Inspection",
      "line": 1472,
      "preview": "--- page 50 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Storage and Handling",
      "line": 1474
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1476,
      "preview": "- Room temperature - 24 hours"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1477,
      "preview": "- Refrigerated (36 - 46 degrees F) - 9 days"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1478,
      "preview": "- Home"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1479,
      "preview": "- Clean shelves and enough space"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1480,
      "preview": "- Do not place in direct sunlight or apply artificial heat"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1481,
      "preview": "- Warm TPN to room temperature before infusing"
    },
    {
      "type": "text",
      "section": "Storage and Handling",
      "line": 1482,
      "preview": "- Review emergency procedures"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Questions:",
      "line": 1485
    },
    {
      "type": "heading",
      "level": 2,
      "section": "George.Ayers@BMHCC.org",
      "line": 1487
    },
    {
      "type": "text",
      "section": "George.Ayers@BMHCC.org",
      "line": 1489,
      "preview": "--- page 51 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 1491
    },
    {
      "type": "text",
      "section": "References",
      "line": 1493,
      "preview": "1. Worthington P, Balint J, Bechtold M, etal. When is Parenteral Nutrition Appropriate? JPEN. 2017 M"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1494,
      "preview": "2. Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NC"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1495,
      "preview": "3. Henrickson E, Corrigan M. Navigating Reimbursement for Home Parenteral Nutrition. NCP. 2013 Oct;2"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1496,
      "preview": "4. Newton D, Driscoll D. Calcium and phosphate compatibility: Revisited again. AJHP. 2008; 65:73-80."
    },
    {
      "type": "text",
      "section": "References",
      "line": 1497,
      "preview": "5. Ayers P, Adams S, Boullata J, etal. A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendati"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1498,
      "preview": "6. Boullata JI, Gilbert K, Sacks G, etal. A.S.P.E.N. clinical guidelines: parenteral nutrition order"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1499,
      "preview": "7. Boullata JI, Holcombe B, Sacks G. Standardized Competencies for Parenteral Nutrition Order Review"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ASPen",
      "line": 1501
    },
    {
      "type": "text",
      "section": "ASPen",
      "line": 1503,
      "preview": "LEADING THE SCIENCE AND"
    },
    {
      "type": "text",
      "section": "ASPen",
      "line": 1504,
      "preview": "PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "ASPen",
      "line": 1505,
      "preview": "Education Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 1507
    },
    {
      "type": "text",
      "section": "References",
      "line": 1509,
      "preview": "8. Mirtallo JM, Ayers P, Boullata J, et al. ASPEN Lipid Injectable Emulsion Safety Recommendations, "
    },
    {
      "type": "text",
      "section": "References",
      "line": 1510,
      "preview": "9. da Silva JSV, Seres DS, Sabino K, et al. ASPEN Consensus Recommendations for Refeeding Syndrome ["
    },
    {
      "type": "text",
      "section": "References",
      "line": 1511,
      "preview": "10. Adams SC, Gura KM, Seres DS, et al. Safe transitions for patients receiving parenteral nutrition"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1512,
      "preview": "11. Allen P, Medicare coverage for home parenteral nutrition: Policy change after almost four decade"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1513,
      "preview": "12. Boullata JI, Salman G, Mirtallo JM, et al. Parenteral nutrition compatibility and stability: pra"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1515,
      "preview": "--- page 52 ---"
    },
    {
      "type": "image",
      "section": "References",
      "line": 1517,
      "content": "![img-27.jpeg](images/663b1ce7c3c3d57b.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Claim CE Credit",
      "line": 1519
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Nutrition (PN) and Home PN",
      "line": 1521
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Deadline to claim CE credit: September 6, 2025",
      "line": 1523
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: September 6, 2025",
      "line": 1525,
      "preview": "- You must complete and submit the evaluation form for an individual session to claim CE credit for "
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: September 6, 2025",
      "line": 1526,
      "preview": "- You must complete the Overall Conference Evaluation to receive your course certificate. You can co"
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: September 6, 2025",
      "line": 1527,
      "preview": "- Detailed Instructions for claiming CE credit are listed in the course handout."
    },
    {
      "type": "heading",
      "level": 3,
      "section": "Pharmacy Participants",
      "line": 1529
    },
    {
      "type": "text",
      "section": "Pharmacy Participants",
      "line": 1531,
      "preview": "PharmD and RPh participants should claim CE immediately after each session to ensure submission to A"
    },
    {
      "type": "image",
      "section": "Pharmacy Participants",
      "line": 1533,
      "content": "![img-28.jpeg](images/4d47794a2cab1f28.png)"
    },
    {
      "type": "text",
      "section": "Pharmacy Participants",
      "line": 1535,
      "preview": "--- page 53 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "aspen <br> American SOCIETY FOR <br> PARENTERAL AND ENTERALNUTRITION",
      "line": 1537
    },
    {
      "type": "heading",
      "level": 2,
      "section": "LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION",
      "line": 1539
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Visit:",
      "line": 1541
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1543,
      "preview": "nutritioncare.org for more information on clinical nutrition and metabolism"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1544,
      "preview": "nutritioncare.org/membership to become a member"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1545,
      "preview": "nutritioncare.org/elearning for on-demand continuing education"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1547,
      "preview": "Follow or like us on:"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1548,
      "preview": "$\\square$ nutritioncare.org/facebook"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1549,
      "preview": "$\\square$ nutritioncare.org/X"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1550,
      "preview": "in nutritioncare.org/linkedin"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1551,
      "preview": "$\\square$ nutritioncare.org/youtube"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1552,
      "preview": "$\\square$ nutritioncare.org/podcasts"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 1554,
      "preview": "--- page 54 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Name, Title, Affiliation",
      "line": 1556
    },
    {
      "type": "text",
      "section": "Name, Title, Affiliation",
      "line": 1558,
      "preview": "Phil Ayers, PharmD, BCNSP, FMSHP, FASHP"
    },
    {
      "type": "text",
      "section": "Name, Title, Affiliation",
      "line": 1559,
      "preview": "Chief, Clinical Pharmacy Services, Mississippi Baptist Medical Center"
    },
    {
      "type": "text",
      "section": "Name, Title, Affiliation",
      "line": 1560,
      "preview": "Associate Clinical Professor, University of Mississippi School of Pharmacy"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Presentation Title",
      "line": 1562
    },
    {
      "type": "text",
      "section": "Presentation Title",
      "line": 1564,
      "preview": "Parenteral Nutrition (PN) and Home PN"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Disclosures",
      "line": 1566
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 1568,
      "preview": "Consultant: American Regent, B. Braun"
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 1569,
      "preview": "Consultant/Speakers Bureau: Fresenius Kabi"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Presentation Overview/Summary",
      "line": 1571
    },
    {
      "type": "text",
      "section": "Presentation Overview/Summary",
      "line": 1573,
      "preview": "This presentation will cover the foundational principles related to parenteral nutrition (PN). Topic"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Learning Objectives",
      "line": 1575
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1577,
      "preview": "At the conclusion of the presentation, the learner will be able to:"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1579,
      "preview": "1. Discuss indications for parenteral nutrition (PN)"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1580,
      "preview": "2. Review parenteral prescription process"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1581,
      "preview": "3. Develop a proper plan for PN monitoring and management"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1582,
      "preview": "4. Identify issues related to safe practice"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Key Takeaways/Fast Facts",
      "line": 1584
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 1586,
      "preview": "- PN is a high risk medication that requires close management in the inpatient and home arena."
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 1587,
      "preview": "- There are roughly 56,000 patients on home PN in the United States."
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 1588,
      "preview": "- Safe delivery of PN is the responsibility of healthcare providers, patients, and caregivers."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Learning Assessment Questions",
      "line": 1591
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1593,
      "preview": "1. Question 1: Peripheral parenteral nutrition is a nutritional support option for patients receivin"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1594,
      "preview": "A. True"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1595,
      "preview": "B. False"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1596,
      "preview": "2. Question 2: 2-in-1 PN will have intravenous lipid emulsion (ILE) piggybacked along with the PN. W"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1597,
      "preview": "A. 8 hours"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1598,
      "preview": "B. 12 hours"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1599,
      "preview": "C. 18 hours"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1600,
      "preview": "D. 24 hours"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1601,
      "preview": "3. Question 3: What is the safe osmolarity limit for the administration of peripheral PN?"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1602,
      "preview": "A. $500 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1603,
      "preview": "B. $900 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1604,
      "preview": "C. $1200 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1605,
      "preview": "D. $1500 \\mathrm{mOsm} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1607,
      "preview": "--- page 55 ---"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1609,
      "preview": "4. Question 4: Which of the following elements can compromise TNA (3-in-1 PN) stability?"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1610,
      "preview": "A. Amino acid final concentration $<4 \\%$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1611,
      "preview": "B. Dextrose final concentration $<10 \\%$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1612,
      "preview": "C. ILE final concentration $<2 \\%$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1613,
      "preview": "D. All of the above"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1614,
      "preview": "5. Question 5: Which of the following lipid injectable emulsions (ILE) contains the highest amount o"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1615,
      "preview": "A. FO-ILE"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1616,
      "preview": "B. OO-SO-ILE"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1617,
      "preview": "C. SO-MCT-OO-FO-ILE"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 1618,
      "preview": "D. SO-ILE"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Learning Assessment Answers:",
      "line": 1620
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 1622,
      "preview": "1. Answer = False; Rationale: Peripheral PN is a short term option for the provision of nutrition su"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 1623,
      "preview": "2. Answer $=$ B; Rationale: Current recommendations state that ILE within a TNA should have a maximu"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 1624,
      "preview": "3. Answer $=$ B; Rationale: To minimize extravasation and pheblitis risk, the recommended osmolarity"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 1625,
      "preview": "4. Answer $=$ D; Rationale: TNA stability is compromised by the following: amino acid final concentr"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 1626,
      "preview": "5. Answer $=$ D; Rationale: SO-ILE contains the highest amount of phytosterol when compared to the o"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 1628
    },
    {
      "type": "text",
      "section": "References",
      "line": 1630,
      "preview": "1. Worthington P, Balint J, Bechtold M, etal. When is Parenteral Nutrition Appropriate? JPEN. 2017 M"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1631,
      "preview": "2. Derenski K, et al. Parenteral Nutrition Basics for the Clinician Caring for the Adult Patient, NC"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1632,
      "preview": "3. Henrickson E, Corrigan M. Navigating Reimbursement for Home Parenteral Nutrition. NCP. 2013 Oct;2"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1633,
      "preview": "4. Newton D, Driscoll D. Calcium and phosphate compatibility: Revisited again. AJHP. 2008; 65:73-80."
    },
    {
      "type": "text",
      "section": "References",
      "line": 1634,
      "preview": "5. Ayers P, Adams S, Boullata J, etal. A.S.P.E.N. Parenteral Nutrition Safety Consensus Recommendati"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1635,
      "preview": "6. Boullata JI, Gilbert K, Sacks G, etal. A.S.P.E.N. clinical guidelines: parenteral nutrition order"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1636,
      "preview": "7. Boullata JI, Holcombe B, Sacks G. Standardized Competencies for Parenteral Nutrition Order Review"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1637,
      "preview": "8. Mirtallo JM, Ayers P, Boullata J, et al. ASPEN Lipid Injectable Emulsion Safety Recommendations, "
    },
    {
      "type": "text",
      "section": "References",
      "line": 1639,
      "preview": "--- page 56 ---"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1641,
      "preview": "9. Boullata JI, Salman G, Mirtallo JM, et al. Parenteral nutrition compatibility and stability: prac"
    },
    {
      "type": "text",
      "section": "References",
      "line": 1642,
      "preview": "10. Allen, P. Medicare coverage for home parenteral nutrition: Policy change after almost four decad"
    }
  ],
  "images": [
    {
      "sha_name": "87821306c5ba38e8.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/87821306c5ba38e8.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/87821306c5ba38e8.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "87821306c5ba38e8"
    },
    {
      "sha_name": "9fc704712b53fa33.png",
      "original_ref": "img-1.jpeg",
      "page": 5,
      "relative_path": "images/9fc704712b53fa33.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/9fc704712b53fa33.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "9fc704712b53fa33"
    },
    {
      "sha_name": "20935371c9b9dc3f.png",
      "original_ref": "img-2.jpeg",
      "page": 5,
      "relative_path": "images/20935371c9b9dc3f.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/20935371c9b9dc3f.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "20935371c9b9dc3f"
    },
    {
      "sha_name": "46f1c63bd9acccb9.png",
      "original_ref": "img-3.jpeg",
      "page": 7,
      "relative_path": "images/46f1c63bd9acccb9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/46f1c63bd9acccb9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "46f1c63bd9acccb9"
    },
    {
      "sha_name": "77ccd0a6a1b24197.png",
      "original_ref": "img-4.jpeg",
      "page": 7,
      "relative_path": "images/77ccd0a6a1b24197.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/77ccd0a6a1b24197.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "77ccd0a6a1b24197"
    },
    {
      "sha_name": "d70217d4692159f6.png",
      "original_ref": "img-5.jpeg",
      "page": 7,
      "relative_path": "images/d70217d4692159f6.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/d70217d4692159f6.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d70217d4692159f6"
    },
    {
      "sha_name": "0016ca21d662da77.png",
      "original_ref": "img-6.jpeg",
      "page": 8,
      "relative_path": "images/0016ca21d662da77.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/0016ca21d662da77.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0016ca21d662da77"
    },
    {
      "sha_name": "9ef5470133ad1ab6.png",
      "original_ref": "img-7.jpeg",
      "page": 8,
      "relative_path": "images/9ef5470133ad1ab6.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/9ef5470133ad1ab6.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "9ef5470133ad1ab6"
    },
    {
      "sha_name": "d46484661136ed47.png",
      "original_ref": "img-8.jpeg",
      "page": 8,
      "relative_path": "images/d46484661136ed47.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/d46484661136ed47.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d46484661136ed47"
    },
    {
      "sha_name": "2f226aa1f826d8f6.png",
      "original_ref": "img-9.jpeg",
      "page": 9,
      "relative_path": "images/2f226aa1f826d8f6.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/2f226aa1f826d8f6.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2f226aa1f826d8f6"
    },
    {
      "sha_name": "0cc618b5a71c1f57.png",
      "original_ref": "img-10.jpeg",
      "page": 9,
      "relative_path": "images/0cc618b5a71c1f57.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/0cc618b5a71c1f57.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0cc618b5a71c1f57"
    },
    {
      "sha_name": "92907d50d5cd04ed.png",
      "original_ref": "img-11.jpeg",
      "page": 12,
      "relative_path": "images/92907d50d5cd04ed.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/92907d50d5cd04ed.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "92907d50d5cd04ed"
    },
    {
      "sha_name": "2f271c5ba2d9068f.png",
      "original_ref": "img-12.jpeg",
      "page": 12,
      "relative_path": "images/2f271c5ba2d9068f.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/2f271c5ba2d9068f.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2f271c5ba2d9068f"
    },
    {
      "sha_name": "c9d82998f0afc111.png",
      "original_ref": "img-13.jpeg",
      "page": 12,
      "relative_path": "images/c9d82998f0afc111.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/c9d82998f0afc111.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c9d82998f0afc111"
    },
    {
      "sha_name": "231011de97055889.png",
      "original_ref": "img-14.jpeg",
      "page": 13,
      "relative_path": "images/231011de97055889.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/231011de97055889.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "231011de97055889"
    },
    {
      "sha_name": "2eac702747e0b442.png",
      "original_ref": "img-15.jpeg",
      "page": 16,
      "relative_path": "images/2eac702747e0b442.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/2eac702747e0b442.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2eac702747e0b442"
    },
    {
      "sha_name": "14fb20167a7a93dc.png",
      "original_ref": "img-16.jpeg",
      "page": 16,
      "relative_path": "images/14fb20167a7a93dc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/14fb20167a7a93dc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "14fb20167a7a93dc"
    },
    {
      "sha_name": "3d3e380cc1aaf0ca.png",
      "original_ref": "img-17.jpeg",
      "page": 17,
      "relative_path": "images/3d3e380cc1aaf0ca.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/3d3e380cc1aaf0ca.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "3d3e380cc1aaf0ca"
    },
    {
      "sha_name": "e57364ee331b74a7.png",
      "original_ref": "img-18.jpeg",
      "page": 29,
      "relative_path": "images/e57364ee331b74a7.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/e57364ee331b74a7.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "e57364ee331b74a7"
    },
    {
      "sha_name": "f602d62d3b64a89d.png",
      "original_ref": "img-19.jpeg",
      "page": 30,
      "relative_path": "images/f602d62d3b64a89d.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/f602d62d3b64a89d.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f602d62d3b64a89d"
    },
    {
      "sha_name": "5cf7e3e64f2a9566.png",
      "original_ref": "img-20.jpeg",
      "page": 34,
      "relative_path": "images/5cf7e3e64f2a9566.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/5cf7e3e64f2a9566.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "5cf7e3e64f2a9566"
    },
    {
      "sha_name": "f3fdab93d14748a4.png",
      "original_ref": "img-21.jpeg",
      "page": 34,
      "relative_path": "images/f3fdab93d14748a4.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/f3fdab93d14748a4.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f3fdab93d14748a4"
    },
    {
      "sha_name": "987e7b5014e6eddb.png",
      "original_ref": "img-22.jpeg",
      "page": 37,
      "relative_path": "images/987e7b5014e6eddb.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/987e7b5014e6eddb.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "987e7b5014e6eddb"
    },
    {
      "sha_name": "0508f81bba3d4a50.png",
      "original_ref": "img-23.jpeg",
      "page": 37,
      "relative_path": "images/0508f81bba3d4a50.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/0508f81bba3d4a50.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0508f81bba3d4a50"
    },
    {
      "sha_name": "4fc487ad1f0ecbb9.png",
      "original_ref": "img-24.jpeg",
      "page": 43,
      "relative_path": "images/4fc487ad1f0ecbb9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/4fc487ad1f0ecbb9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4fc487ad1f0ecbb9"
    },
    {
      "sha_name": "d661fe752daa890c.png",
      "original_ref": "img-25.jpeg",
      "page": 48,
      "relative_path": "images/d661fe752daa890c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/d661fe752daa890c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d661fe752daa890c"
    },
    {
      "sha_name": "661bb07e3fab56ff.png",
      "original_ref": "img-26.jpeg",
      "page": 49,
      "relative_path": "images/661bb07e3fab56ff.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/661bb07e3fab56ff.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "661bb07e3fab56ff"
    },
    {
      "sha_name": "663b1ce7c3c3d57b.png",
      "original_ref": "img-27.jpeg",
      "page": 52,
      "relative_path": "images/663b1ce7c3c3d57b.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/663b1ce7c3c3d57b.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "663b1ce7c3c3d57b"
    },
    {
      "sha_name": "4d47794a2cab1f28.png",
      "original_ref": "img-28.jpeg",
      "page": 52,
      "relative_path": "images/4d47794a2cab1f28.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/ASPEN Parenteral Nutrition (PN) and Home PN/images/4d47794a2cab1f28.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4d47794a2cab1f28"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754696305",
    "ts": "2025-08-08T23:38:25.136549+00:00"
  }
}